论文部分内容阅读
目的对比分析干扰素α-1b(IFN-α1b)雾化吸入与肌肉注射治疗小儿呼吸道合胞病毒(RSV)感染的疗效与安全性。方法选取2014年1月-2015年5月,我院住院治疗的.RSV感染患儿156例,按照随机数字表法分为A组和B组,各78例。两组均予以常规治疗,A组予以IFN-α雾化吸入(1μg/kg),B组予以IFN-α1b肌注(1μg/kg),对比两组的疗效与不良反应。结果 A组治疗后Lowell评分及MMRC评分均低于B组(P<0.05);A组的体温复正时间、肺部罗音消失时间、咳嗽咳痰消失时间、白细胞复正时间与住院时间均较B组缩短(P<0.05);治疗后A组的免疫指标(CD3、CD4、CD8、CD4/CD8)均较B组改善(P<0.05)。结论 IFN-α1b治疗小儿RSV感染疗效显著、安全可靠,且雾化吸入较肌肉注射疗效更好,能够更快地促进临床症状体征的恢复,缩短病程,调节机体免疫功能,值得推广应用。
Objective To compare the efficacy and safety of interferon α-1b (IFN-α1b) inhalation and intramuscular injection in the treatment of children with respiratory syncytial virus (RSV) infection. Methods From January 2014 to May 2015, 156 cases of children with .RSV infection hospitalized in our hospital were divided into group A and group B according to the random number table method, 78 cases in each group. Both groups were given routine treatment. Group A received inhalation of IFN-α (1μg / kg) and group B received IFN-α1b intramuscular injection (1μg / kg). The curative effect and adverse reactions of the two groups were compared. Results The Lowell score and MMRC score of group A were lower than that of group B after treatment (P <0.05). The time of body temperature recovery, the time of lung rales disappearance, the disappearance of cough and sputum, the recovery time of leukocytes and the length of stay in group A (P <0.05). After treatment, the immune indexes (CD3, CD4, CD8, CD4 / CD8) of group A were improved compared with group B (P <0.05). Conclusion The therapeutic effect of IFN-α1b in children with RSV infection is significant, safe and reliable. Compared with intramuscular injection, the therapeutic effect of IFN-α1b is better than that of intramuscular injection. It can promote the recovery of clinical symptoms and signs more quickly, shorten the course of disease and regulate immune function.